What is the main purpose of this 8-K filing?

This 8-K filing serves two primary purposes: to report Medtronic's full-year and fourth-quarter fiscal year 2022 financial results, and to announce a strategic joint venture with DaVita Inc. to form a new, independent kidney care-focused company called NewCo.

What is Medtronic contributing to the new kidney care company (NewCo)?

Medtronic is contributing its entire Renal Care Solutions (RCS) business to NewCo. This business segment is part of Medtronic's Respiratory, Gastrointestinal, and Renal division and generated $325 million in revenue during fiscal year 2022.

What is the expected financial impact of this NewCo transaction on Medtronic?

Medtronic anticipates that the transaction will not have a material impact on its adjusted earnings per share in its current fiscal year 2023, or at any point in the following few fiscal years. Medtronic and DaVita will share equal equity in NewCo.

How is Medtronic being compensated for the contribution of its Renal Care Solutions business?

Medtronic will receive value from DaVita through a cash payment, the contribution of certain non-cash assets to NewCo, and potential additional consideration if NewCo achieves specific regulatory and commercial milestones. The total potential value to Medtronic from these components is up to $400 million. Additionally, both companies will contribute $200 million in cash to launch NewCo.

When is this NewCo transaction expected to be completed?

The transaction is expected to close in calendar year 2023, subject to customary regulatory approvals and other closing conditions.

MDT 8-K: Earnings & Results & Regulation FD

Summary

Medtronic plc filed an 8-K on May 26, 2022, primarily to disclose its fourth quarter and full-year fiscal year 2022 financial results and a significant strategic partnership. In addition to reporting financial outcomes for FY2022, the company announced a joint venture with DaVita Inc. to form a new, independent kidney care-focused medical device company, referred to as "NewCo". This transaction involves Medtronic contributing its entire Renal Care Solutions (RCS) business, which generated $325 million in FY2022 revenue, to NewCo. From an investor's perspective, the formation of NewCo is structured to have a minimal impact on Medtronic's adjusted earnings per share in the near term (FY2023 and a few subsequent years). Medtronic and DaVita will share equal equity in NewCo, with DaVita providing a cash payment and non-cash assets, plus potential contingent consideration tied to milestones, which could total up to $400 million in value for Medtronic. Both companies will also contribute $200 million in cash to launch NewCo. The company plans to exclude the RCS revenue from its organic revenue growth calculations for a specified period post-transaction, which is expected to close in calendar year 2023.

Key Highlights

1Medtronic announced a joint venture with DaVita Inc. to create a new, independent kidney care-focused medical device company (NewCo).
2Medtronic will contribute its entire Renal Care Solutions (RCS) business, which had FY2022 revenue of $325 million, to NewCo.
3The transaction is not expected to materially impact Medtronic's adjusted earnings per share in FY2023 or the following few fiscal years.
4Medtronic and DaVita will hold equal equity interests in NewCo.
5Medtronic could receive up to $400 million in value from the transaction, comprising DaVita's cash payment, non-cash asset contribution, and milestone-based contingent consideration.
6Both companies will contribute approximately $200 million in cash to fund the launch of NewCo.
7Medtronic plans to exclude prior year RCS revenue from its organic revenue growth calculations post-transaction for the first 12 months.

Medtronic plc 8-K Report, Financial Results (May 26, 2022)

Summary

Key Highlights

Frequently Asked Questions